Although autophagy is generally considered a prosurvival mechanism that preserves viability, there is evidence that it could drive an alternative programmed cell death pathway in cells with defects in apoptosis. Because the inhibition of autophagic activity promotes resistance to both chemotherapy and external beam radiation in papillary thyroid cancer (PTC), we determined if RAD001, a potent activator of autophagy, improves the efficacy of either therapy. We found that RAD001 increased the expression level of light chain 3-II, a marker for autophagy, as well as autophagosome formation in cell lines and in human PTC ex vivo. RAD001 sensitized PTC to doxorubicin and external beam radiation in a synergistic fashion, suggesting that combination therapy could improve therapeutic response at less toxic concentrations. The effects of RAD001 were abrogated by RNAi knockdown of the autophagy-related gene 5, suggesting that RAD001 acts, in part, by enhancing autophagy. Because the synergistic activity of RAD001 with doxorubicin and external radiation suggests distinct and complementary mechanisms of action, we characterized how autophagy modulates signaling pathways in PTC. To do so, we performed kinome profiling and discovered that autophagic activation resulted in Src phosphorylation and Met dephosphorylation. Src inhibition did not reverse the effects of RAD001, whereas Met inhibition reversed the effects of autophagy blockade on chemosensitivity. These results suggest that the anticancer effects of autophagic activation are mediated largely through Met. We conclude that RAD001 induces autophagy, which enhances the therapeutic response to cytotoxic chemotherapy and external beam radiation in PTC. Mol Cancer Res; 8(9); 1217–26. ©2010 AACR.

This article is featured in Highlights of This Issue, p. 1173

Thyroid cancer is the most common endocrine malignancy and is responsible for the majority of deaths from endocrine cancer (1). Papillary thyroid cancer (PTC) accounts for approximately 80% of thyroid cancers. Although PTC is generally associated with favorable outcomes after surgical resection and radioactive iodine ablation, it is the most common histologic subtype in patients with locally advanced disease (2, 3). Doxorubicin is the only Food and Drug Administration–approved chemotherapy agent for advanced PTC that does not trap radioactive iodine; however, intrinsic resistance to doxorubicin results in limited efficacy and it is rarely used for these patients (4).

RAD001 (everolimus, Afinitor), a rapamycin analogue, is an oral mammalian target of rapamycin (mTOR) inhibitor. mTOR is an intracellular protein that acts as a central regulator of multiple signaling pathways induced by insulin-like growth factor, epidermal growth factor, platelet-derived growth factor, vascular endothelial growth factor, and amino acids that mediate abnormal growth, proliferation, and angiogenesis (5). RAD001 was recently approved for the treatment of papillary renal carcinoma (6), a malignancy driven by an activating Met mutation (7). Although we are now testing the therapeutic efficacy of RAD001 in advanced PTC, its mechanism of action in this context is unknown.

RAD001 stimulates autophagy (8, 9), a highly conserved process that entails the degradation of intracellular components through the lysosomal machinery to regenerate metabolites for energy and growth (10, 11). In many contexts, autophagy promotes cell survival under stressful conditions such as nutrient and growth factor deprivation (12, 13). However, excess or prolonged autophagy could promote an alternative mechanism that leads to programmed cell death, which is particularly relevant in cancers that are defective in apoptosis (14, 15). Prior work has shown that PTC is intrinsically resistant to cytotoxic chemotherapies because of defects in apoptosis (16).

We previously observed that inhibition of autophagy decreased PTC sensitivity to doxorubicin and external beam radiation (17). This result led us to hypothesize that RAD001 could enhance cancer cell response to these therapies through the activation of autophagy. In the current study, we found that the combined effects of RAD001 and doxorubicin together exceeded the sum of their individual effects. To understand the complementary activity of RAD001, we used kinome-wide analysis to determine how RAD001 affects signaling pathways. We found that RAD001 and autophagic activation inhibit Met phosphorylation, an event that imparts the effects of RAD001 on chemosensitivity and radiosensitivity.

Materials

Mouse anti-human microtubule-associated protein 1 light chain 3 (LC3) antibody was purchased from MBL International Cooperation. Mouse anti-actin antibody, pan Ab-5 was purchased from Neomarker. Rabbit anti-human Atg-5, Src, phosphorylated Src Tyr416, Met, phosphorylated Met Tyr1234, cleaved caspase-3 Asp175, phosphorylated histone H3 Ser10, antibodies were purchased from Cell Signaling. Mouse anti-human Ki-67 antibody was obtained from BD Transduction Laboratories. Rabbit anti-human p62 antibody was from Abgent. Secondary horseradish peroxidase–conjugated mouse and rabbit antibodies were obtained from Vector Laboratories. 3-Methyladenine (3-MA), a class III phosphoinositide-3-kinase inhibitor widely used as autophagy inhibitor reported to act specifically on the autophagic/lysosomal pathway of degradation (13), was purchased from Calbiochem. Doxorubicin was obtained from Fluka. RAD001, an mTOR inhibitor that induces autophagy (18), was obtained from Novartis Pharmaceutical. PHA665752, a selective small molecule inhibitor of Met (19), was obtained from Pfizer, Inc. Dasatinib obtained from Broad Institute was synthesized as previously described (20).

Cell culture and RNAi transfections

The human PTC cell lines TPC-1 and 8505-C were cultured as described previously (21). TPC-1 cells were obtained from Dr. Orlo H. Clark (University of California at San Francisco, San Francisco, CA) and 8505-C cells were obtained from Dr. Sareh Parangi (Massachusetts General Hospital, Boston, MA) within the last 5 years and tested within the last 6 months by morphology check by microscope and growth curve analysis according to the Cell Line Verification Test Recommendations (American Type Culture Collection, technical bulletin no. 8, 2008). TPC-1 and 8505-C cells were used throughout passages 12 to 18 and 28 to 35 in this study. Cells were subcultured at 80% confluency by trypsinization [in a 0.5% (v/v) trypsin solution supplemented with 0.2% (v/v) EDTA]. Cells were transfected with scrambled short interfering RNA (siRNA) or Atg-5 prevalidated siRNA duplex (the target sequences were no. 1, AACCTTTGGCCTAAGAAGAAA; no. 2, AAGACTTACCGGACCACTGAA; Qiagen) using LipofectAMINE 2000 reagent (Invitrogen), according to the instructions of the manufacturer. All transfections were done in six-well plates and cells were processed 48 hours after transfection.

Autophagy assay

Autophagosome formation was also confirmed by the appearance of punctate fluorescence from exogenous GFP-fused LC3, a specific lysosomal/autophagic biochemical vacuole marker (10). Cells were transfected with EGFP-LC3 plasmid (Addgene) using LipofectAMINE 2000 reagent. Forty-eight hours after transfection, cells were treated with DMSO and RAD001 (20 nmol/L) for 24 hours. The fluorescence of EGFP-LC3 was observed under a fluorescence microscope.

Human thyroid tumor tissue specimens

Human PTC tissues and normal adjacent thyroid tissue were obtained from thyroidectomy specimens resected from surgery patients. The specimens were immediately frozen in liquid nitrogen upon removal from the patients and the samples were stored frozen until the time of protein extraction. Tissue lysates were prepared using radioimmunoprecipitation assay buffer containing protease inhibitor cocktail as described previously (22). The Institutional Review Board of Brigham & Women's Hospital in Boston, MA approved this protocol (protocol number: 1999-P-001331/5).

Western blotting

Cell lysates were prepared and analyzed by Western blotting as described previously (21).

Transmission electron microscopy and morphometric analysis

Cultured PTC tissue specimens were washed with serum-free DMEM (Invitrogen) followed by a brief wash in 1 mol/L of cacodylate buffer and then fixed with 2.5% glutaraldehyde with 0.1 mol/L of sodium cacodylate buffer for 1 hour. Fixed cells and PTC tissue specimens were processed at the Harvard Medical School Transmission Electron Microscopy core facility by using protocols described previously (23) using a JEOL-60kV microscope (JEOL). Morphometric analysis was done as previously described (24). For each control or treatment group, 100 cells were randomly chosen from the fields for quantification of autophagic features. Closed vacuoles with double membranes containing cytosol and/or organelles were considered autophagic vacuoles (11). Cells with ≥10 autophagic vacuoles were determined as autophagic cells.

Ex vivo PTC tumor specimen culture and immunohistochemistry

A piece of each human tissue specimen was excised using sterile techniques. Vital specimens (0.5 mm3) were cultured in Millicell cell culture inserts (Millipore) containing 600 μL of DMEM/F12 medium with 15 mmol/L of HEPES (Sigma-Aldrich) supplemented with GlutaMAX I (Invitrogen) at 37°C and 5% CO2 for 8 hours in the absence or presence of doxorubicin (1 μmol/L). Immunohistochemical analysis of Ki-67, p62, and cleaved caspase-3 was done as described previously (25). p62, a ubiquitin-binding scaffold protein, is degraded by autophagy and is a marker of autophagy (26).

Clonogenic survival assay and IC50 determination

For cell survival determination, standard clonogenic survival assays were done as previously described (27), with minor modifications. Eight hundred cells were plated and then coincubated with doxorubicin (final concentrations of 200, 100, 50, 20, 10, 5, or 1 nmol/L) or medium without doxorubicin and cultured in a humidified CO2 incubator at 37°C for 10 to 14 days. Cells were fixed for 15 minutes with a 3:1 methanol/acetic acid solution and stained for 15 minutes with 0.5% crystal violet (Sigma-Aldrich) in methanol. After staining, colony numbers were counted. IC50 (a concentration of the compound causing 50% inhibition) values were determined. The mean ± SEM of triplicate samples was determined for each treatment. The data was analyzed by plotting the clonogenic survival rate (number of colonies in treated plates/number of colonies in controls) versus the doxorubicin concentration.

MTS cell proliferation assay

The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay (Celltiter96 AQ, Promega) was used to assess RAD001 and doxorubicin effects on cell viability as previously described (21).

Radiosensitivity assay

For radiation experiments, cells were trypsinized, replated, and incubated for an additional 24 hours under standard conditions. Eight hundred cells were plated and then irradiated with doses ranging from 0 to 6 Gy (Gammacell 1000 apparatus, 200 kV, 15 mA, 1 Gy/min; Atomic Energy of Canada, Ottawa, Canada). Forty-eight hours after irradiation, the medium was replaced with fresh medium and then subjected to clonogenic survival assay. The mean ± SD of triplicate samples was determined for each treatment. The data was analyzed by plotting the log of the surviving fraction (number of colonies) versus radiointensity.

Kinome array analysis

We did a bead-based profiling of tyrosine kinase phosphorylation using individual Luminex xMAP microspheres (Luminex) in an immunosandwich assay, as previously described (28). In brief, an antibody-based kinase phosphorylation assay for a panel of 71 unique tyrosine kinases was used to comprehensively evaluate the effects of Atg-5 knockdown and RAD001 treatment. Scrambled or Atg-5 siRNA–transfected cells were washed in ice-cold PBS and harvested in 1× cell lysis buffer (Cell Signaling) supplemented with a cocktail of protease inhibitors (Sigma-Aldrich). The data was acquired with a Luminex FlexMAP 3D instrument (Luminex) according to the instructions of the manufacturer. Subtracting the sample and antibody background signals normalized raw values. Normalized values were considered positive if they were ≥10. The preprocessed data were converted into .gct files and analyzed with GenePattern 3.0 (the Broad Institute, Cambridge, MA).

Statistical analysis

Differences between treatment groups were evaluated with a two-tailed independent Student's t test. Each assay was done in triplicate, and a value of P < 0.05 was considered statistically significant. We defined positive treatment as “synergistic” when agents had a combined effect on the inhibition of proliferation greater than the sum of their individual effects. To display such activity, we determined the minimum concentration of each agent necessary to achieve a significant effect (ICmin) and then determined the combined activity at the ICmin concentrations of both agents. The correlation between autophagic cell numbers in DMSO- and RAD001-treated cells was analyzed by χ2 testing.

RAD001 induces autophagy in PTC

To determine if RAD001 induces autophagy in PTC, we treated 8505-C and TPC-1 cells with RAD001 at doses previously shown to inhibit mTOR signaling in cell cultures (18). Then, we assayed the expression level of the LC3-II protein, which is generated when microtubule-associated protein 1A/1B LC3 undergoes autosomal breakdown. Conjugation of ubiquitous cytosolic LC3-I to phosphatidylethanolamine produces the LC3-phosphatidylethanolamine conjugate (LC3-II), which is recruited to autophagosomal membranes and is a reliable marker for autophagic activity. Immunoblotting revealed that 20 nmol/L of RAD001 was required to significantly increase the expression level of the LC3-II protein (Fig. 1A).

We next determined if the ectopic expression of LC3 affected the action of RAD001. PTC cells were transfected with a GFP-labeled LC3 plasmid; we then observed a significant increase in punctate fluorescence in RAD001-treated cells, which reflects the formation of autophagosomes (Fig. 1B). We also determined how siRNA knockdown of Atg-5, which is required for autophagy (29), affected RAD001 activity. Therefore, we used two distinct siRNAs that targeted nonoverlapping regions of the Atg-5 mRNA for this experiment. We found that Atg-5 depletion by the siRNAs, which are designated as nos. 1 and 2, abrogated the RAD001-mediated increase in LC3-II (Fig. 1C).

To further confirm the presence of autophagy, we did electron microscopy to visualize autophagosomes (Fig. 2). Morphometric analysis showed that RAD001 significantly increased the formation of autophagic vacuoles, which are characterized as double-membrane vacuoles containing cytoplasmic contents (24). This further shows that RAD001 induces autophagy in PTC (Table 1).

We next determined if RAD001 induces autophagic activity in human PTC specimens. To that end, we harvested thyroid specimens from patients undergoing resection of thyroid cancer and treated these with RAD001. Autophagy was evaluated by immunoblotting for the LC3-II protein and by electron microscopy. We found that RAD001 induced LC3-II protein expression in three consecutive tumors, demonstrating the ability of RAD001 to induce autophagy in human specimens (Fig. 3A). Likewise, RAD001-treated human ex vivo specimens displayed a substantial increase in autophagosomes that were visualized by electron microscopy, providing further evidence that autophagy is induced by RAD001 (Fig. 3B). RAD001-treated specimens showed a significant decrease in endogenous p62 expression, another marker for autophagy (26), further demonstrating the activation of autophagy in these human operative specimens (Fig. 3A and C). RAD001 did not change caspase-3 cleavage in PTC tissue, indicating that it had no significant effects on apoptosis (Fig. 3D). Together, our in vitro and ex vivo results indicate that RAD001 effectively activates autophagy in PTC.

RAD001 and doxorubicin have synergistic activity in PTC

To determine the effect of RAD001 on doxorubicin chemosensitivity, we first determined a baseline IC50 of doxorubicin of 98.61 and 52.97 nmol/L in 8505-C and TPC-1 cells, respectively (Supplementary Fig. S1). Treatment with 20 nmol/L of RAD001 decreased the IC50 by 48% and 38% in 8505-C and TPC-1 cells, respectively. The effect of RAD001 on chemosensitivity was abrogated with Atg-5 siRNAs, suggesting that the effects of RAD001 on doxorubicin chemosensitivity are mediated through autophagy (Supplementary Fig. S1).

Using the MTS and clonogenic survival assays, we determined that the minimum inhibitory concentration (ICmin) of doxorubicin was 20 and 50 nmol/L in 8505-C and TPC-1 cells, respectively (Fig. 4A and C, left). The ICmin of RAD001 was 5 and 10 nmol/L in 8505-C and TPC-1 cells, respectively (Fig. 4A and C, right). In an MTS assay, the combination of doxorubicin and RAD001, at their ICmin, decreased cell survival by 293% and 299%, in comparison with doxorubicin alone in 8505-C and TPC-1 cells, respectively. The combination of both agents exceeded the additive effects of each individual agent (Fig. 4B). In a clonogenic assay, the combination of doxorubicin with RAD001 at their ICmin decreased cell survival by 319% and 348%, in comparison with doxorubicin alone in 8505-C and TPC-1 cells, respectively (Fig. 4C). Consistent with synergistic activity, the efficacy of both agents exceeded the additive effects of the agents (Fig. 4D).

RAD001 improves radiosensitivity in PTC

Because external beam radiation is an important therapeutic modality for patients with locally advanced PTC, we determined if RAD001 could improve radiosensitivity in PTC cells. We treated 8505-C and TPC-1 cells with DMSO (control) or 20 nmol/L of RAD001 and then exposed them to radiation doses ranging from 0 to 6 Gy (Fig. 5A). PTC cells treated with RAD001 had a significant improvement in sensitivity to various doses of radiation. This effect was reversed when cells were treated with Atg-5 siRNA, suggesting that the radiosensitizing effects of RAD001 are mediated through autophagy.

In ex vivo experiments of human PTC, RAD001 activated autophagy, but did not seem to activate apoptosis (Fig. 5B). RAD001, in combination with doxorubicin or radiation, exhibited additive effects on the accumulation of LC3-II and the inhibition of histone H3 phosphorylation. No basal or additive caspase-3 cleavage signals were observed with RAD001 treatment, even when the specimens were treated with doxorubicin or external radiation. Consistent with our in vitro results, RAD001 activated autophagy and potentiated the autophagic activation caused by doxorubicin or external beam radiation in ex vivo specimens.

The effects of autophagic activation on chemosensitivity and radiosensitivity are mediated through Met

Because our results suggested that RAD001 has a distinct and complementary mechanism of action with doxorubicin, we determined the effects of RAD001 on cell signaling pathways. We used a kinome array technique, based on the multiplexed coupling of tyrosine kinase–specific antibodies to polystyrene microspheres beads, to simultaneously determine the phosphorylation status of 71 unique tyrosine kinases. In this analysis, Src and Met were the most differentially phosphorylated in scrambled versus Atg-5 siRNA–transfected cells, and in control versus RAD001-treated cells (Fig. 6A). We validated the kinome array results by immunoblotting; this confirmed that Atg-5 siRNA decreased Src but increased Met activity, whereas RAD001 increased Src but decreased Met activity (Fig. 6B).

Because autophagic activation modulated Src and Met, we determined if either or both were essential for the augmentation in chemosensitivity and radiosensitivity observed during autophagy. We treated PTC cell lines with dasatinib, a Src inhibitor, to determine if it reversed the effects of RAD001. RAD001 decreased the IC50 by 36% and 31%, whereas RAD001 plus dasatinib decreased the IC50 by 62% and 52% in 8505-C and TPC-1 cells, respectively. Furthermore, the addition of dasatinib to RAD001 also significantly improved radiosensitivity (Supplementary Fig. S3). Therefore, these results show that dasatinib enhanced, rather than attenuated, the anticancer effects of RAD001.

In contrast, Atg-5 siRNA increased the IC50 by 81% and 71%, whereas Atg-5 siRNA in combination with the Met inhibitor PHA665752 increased the IC50 by only 3% and 6% in 8505-C and TPC-1 cells, respectively. Therefore, PHA665752 abrogated the effects of Atg-5 knockdown on chemosensitivity. Furthermore, RAD001 and PHA665752 induced similar effects on chemosensitivity and radiosensitivity with no significant additive effects in combination (Supplementary Figs. S3A and S4A). Together, these results suggest that the effects of autophagic activation on chemosensitivity and radiosensitivity are mediated largely through Met.

RAD001 potently activates autophagy in PTC cell lines and human PTC specimens maintained ex vivo. RAD001 synergistically enhances both chemosensitivity to doxorubicin and radiosensitivity, and seems to do so through autophagy. That RAD001 elicits these effects is of considerable interest as it inhibits mTOR, a signaling protein that is a convergence point for many signaling pathways. Furthermore, mTOR elicits the cellular response to extracellular stimuli by mediating changes of cellular protein synthesis. That RAD001 acts through autophagy is supported by the observation that Atg-5 knockdown completely abrogates the effect of RAD001 on chemosensitivity. Because Atg-5 is an essential component of the autophagosome with no other known function, our results suggest that RAD001 enhancement of chemosensitivity is mediated through autophagy.

Because autophagy is often considered a prosurvival phenomenon, our findings might be somewhat unexpected. One explanation for our observations is that RAD001 might promote autophagy-mediated programmed cell death, a nonapoptotic escape pathway important in cells that are defective or deficient in apoptosis (30). PTC is intrinsically resistant to cytotoxic chemotherapies, partly due to defects in apoptosis (16). This is relevant to a variety of malignancies, many with known deficiencies in apoptosis that are resistant to conventional cytotoxic chemotherapy, such as gemcitabine-refractory metastatic pancreatic cancer (3137).

Because of the potent synergistic anticancer effects of RAD001 with doxorubicin, we characterized the effects of RAD001 on cell signaling. The most prominent alterations detected from autophagy blockade with Atg-5 knockdown were Met activation and Src inactivation. Consistent with this observation, the most prominent alterations during autophagy activation by RAD001 were Met inactivation and Src activation. Our results suggest that the chemosensitizing and radiosensitizing effects of autophagic activation are mediated largely through Met. If the chemosensitizing effects of RAD001 were mediated through Src activation, Src inhibition would at least partially abrogate these effects. However, a Src inhibitor potentiated, rather than reversed, the chemosensitization from RAD001. Of note, a recent report showed that Src inhibition activated autophagy in glioma cells (38). This report, and the results of our current study, suggest that combination treatment with a Src inhibitor might increase RAD001 efficacy.

In contrast, Atg-5 knockdown increased doxorubicin chemoresistance and Met phosphorylation. The addition of a Met inhibitor to Atg-5 knockdown cells abrogated this effect. This suggests that the effects of autophagy on chemosensitivity are mediated mostly through Met. This is the first study to directly associate autophagic activation with Met activation. A recent study showed that a cyclooxygenase-2 inhibitor downregulated both mTOR expression and Met activation in hepatocellular carcinoma cells (39). Although this was associated with autophagic activation, the association between autophagy and Met phosphorylation was not identified. Interestingly, RAD001 has excellent activity in papillary renal carcinoma, a malignancy driven by a constitutively active Met mutation (6, 7).

Ionizing radiation induces autophagy in various cell lines (4043). However, it is unclear if autophagy promotes or prevents cell death in cancer cells exposed to ionizing radiation. In mouse embryonic fibroblasts, RAD001 promotes autophagy and reduces radioresistance (41). Furthermore, autophagy inhibition by Atg-5 siRNA or 3-MA increases the radiosensitivity of human lung cancer cells (42). In contrast, treatment with 3-MA or bafilomycin A1, another autophagy inhibitor, radiosensitizes malignant glioma cells, suggesting that autophagy may provide protection from ionizing radiation (40). Our data show that RAD001 by itself increases the radiosensitivity of PTC (Fig. 5). These observations imply that the autophagic response to radiation exposure might be a prosurvival or prodeath mechanism, depending on cellular context.

There are several issues that remain to be addressed. First, the concept of autophagy-driven programmed cell death is controversial. Some cancer cell lines that lack the machinery to execute apoptosis could still die in a nonnecrotic manner in a process associated with autophagy (44), which can be abrogated by knocking down Atg-5 (45). In the end, it is difficult to determine if autophagy is the mechanism of cell death, or if it is a survival response triggered by stresses that occur near death (46).

Here, we used RAD001 to induce autophagy. Because mTOR is an important regulator of several effector pathways, it is unclear how much of its anticancer activity could be attributed to autophagy. However, our experiments using Atg-5 knockdown suggest an autophagy-specific effect for RAD001. Lastly, our work did not include in vivo studies, and as such, we did not investigate issues related to efficacy and toxicity in animals. However, RAD001 trials are already under way for other malignancies, and the toxicity profiles are acceptable (47). We have already initiated a RAD001 trial for patients with advanced PTC resistant to radioactive iodine treatment (Dana-Farber Cancer Institute protocol no. 09-049).

In summary, the induction of autophagy in combination with cytotoxic chemotherapy is a promising therapeutic strategy for patients with refractory PTC. The synergistic effects of RAD001 and doxorubicin suggest that improvements in therapeutic efficacy could be achieved with lower overall toxicity. RAD001 improves sensitivity to doxorubicin and ionizing radiation through the attenuation of Met. Future studies should determine the efficacy and safety of combining RAD001 with conventional cytotoxic chemotherapy and radiation therapy for malignancies that are resistant to conventional therapy due to intrinsic resistance to apoptosis.

No potential conflicts of interest were disclosed.

We thank Dr. Orlo H. Clark (University of California at San Francisco, San Francisco, CA) for kindly providing TPC-1 cells; Dr. Sareh Parangi (Massachusetts General Hospital, Boston, MA) for providing 8505-C cells; and Adelaide Carothers for her assistance with this work.

Grant Support: Osteen Junior Faculty Research Grant from the Department of Surgery at Brigham and Women's Hospital.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1
Gimm
O
. 
Thyroid cancer
.
Cancer Lett
2001
;
163
:
143
56
.
2
Fassnacht
M
,
Kreissl
MC
,
Weismann
D
,
Allolio
B
. 
New targets and therapeutic approaches for endocrine malignancies
.
Pharmacol Ther
2009
;
123
:
117
41
.
3
Kebebew
E
,
Clark
OH
. 
Locally advanced differentiated thyroid cancer
.
Surg Oncol
2003
;
12
:
91
9
.
4
Hanna
NN
,
McGrath
PC
,
Sloan
DA
,
Kenady
DE
. 
Advances in the pathogenesis and treatment of thyroid cancer
.
Curr Opin Oncol
1999
;
11
:
42
7
.
5
Bjornsti
MA
,
Houghton
PJ
. 
The TOR pathway: a target for cancer therapy
.
Nat Rev Cancer
2004
;
4
:
335
48
.
6
Agarwala
SS
,
Case
S
. 
Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review
.
Oncologist
2010
;
15
:
236
45
.
7
Jeffers
M
,
Schmidt
L
,
Nakaigawa
N
, et al
. 
Activating mutations for the met tyrosine kinase receptor in human cancer
.
Proc Natl Acad Sci U S A
1997
;
94
:
11445
50
.
8
Easton
JB
,
Houghton
PJ
. 
mTOR and cancer therapy
.
Oncogene
2006
;
25
:
6436
46
.
9
Johnson
BE
,
Jackman
D
,
Janne
PA
. 
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer
.
Clin Cancer Res
2007
;
13
:
s4628
31
.
10
Kondo
Y
,
Kanzawa
T
,
Sawaya
R
,
Kondo
S
. 
The role of autophagy in cancer development and response to therapy
.
Nat Rev Cancer
2005
;
5
:
726
34
.
11
Levine
B
,
Klionsky
DJ
. 
Development by self-digestion: molecular mechanisms and biological functions of autophagy
.
Dev Cell
2004
;
6
:
463
77
.
12
Kuma
A
,
Hatano
M
,
Matsui
M
, et al
. 
The role of autophagy during the early neonatal starvation period
.
Nature
2004
;
432
:
1032
6
.
13
Lum
JJ
,
Bauer
DE
,
Kong
M
, et al
. 
Growth factor regulation of autophagy and cell survival in the absence of apoptosis
.
Cell
2005
;
120
:
237
48
.
14
Pattingre
S
,
Tassa
A
,
Qu
X
, et al
. 
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy
.
Cell
2005
;
122
:
927
39
.
15
Clarke
PG
. 
Developmental cell death: morphological diversity and multiple mechanisms
.
Anat Embryol (Berl)
1990
;
181
:
195
213
.
16
Stassi
G
,
Todaro
M
,
Zerilli
M
, et al
. 
Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10
.
Cancer Res
2003
;
63
:
6784
90
.
17
Lin
CI
,
Whang
EE
,
Abramson
MA
, et al
. 
Autophagy: a new target for advanced papillary thyroid cancer therapy
.
Surgery
2009
;
146
:
1208
14
.
18
Vignot
S
,
Faivre
S
,
Aguirre
D
,
Raymond
E
. 
mTOR-targeted therapy of cancer with rapamycin derivatives
.
Ann Oncol
2005
;
16
:
525
37
.
19
Puri
N
,
Khramtsov
A
,
Ahmed
S
, et al
. 
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts
.
Cancer Res
2007
;
67
:
3529
34
.
20
Lombardo
LJ
,
Lee
FY
,
Chen
P
, et al
. 
Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
.
J Med Chem
2004
;
47
:
6658
61
.
21
Lin
CI
,
Whang
EE
,
Abramson
MA
, et al
. 
Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells
.
Biochem Biophys Res Commun
2009
;
379
:
626
31
.
22
Lin
CI
,
Whang
EE
,
Donner
DB
, et al
. 
Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer
.
Mol Cancer Res
2009
;
7
:
1655
62
.
23
Debnath
J
,
Mills
KR
,
Collins
NL
,
Reginato
MJ
,
Muthuswamy
SK
,
Brugge
JS
. 
The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini
.
Cell
2002
;
111
:
29
40
.
24
Yu
L
,
Alva
A
,
Su
H
, et al
. 
Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8
.
Science
2004
;
304
:
1500
2
.
25
Carothers
AM
,
Moran
AE
,
Cho
NL
,
Redston
M
,
Bertagnolli
MM
. 
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor
.
Cancer Res
2006
;
66
:
6432
8
.
26
Bjorkoy
G
,
Lamark
T
,
Pankiv
S
,
Overvatn
A
,
Brech
A
,
Johansen
T
. 
Monitoring autophagic degradation of p62/SQSTM1
.
Methods Enzymol
2009
;
452
:
181
97
.
27
Mirabelli
CK
,
Johnson
RK
,
Sung
CM
,
Faucette
L
,
Muirhead
K
,
Crooke
ST
. 
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models
.
Cancer Res
1985
;
45
:
32
9
.
28
Du
J
,
Bernasconi
P
,
Clauser
KR
, et al
. 
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy
.
Nat Biotechnol
2009
;
27
:
77
83
.
29
Pyo
JO
,
Jang
MH
,
Kwon
YK
, et al
. 
Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death
.
J Biol Chem
2005
;
280
:
20722
9
.
30
Buytaert
E
,
Callewaert
G
,
Vandenheede
JR
,
Agostinis
P
. 
Deficiency in apoptotic effectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum
.
Autophagy
2006
;
2
:
238
40
.
31
Homicsko
K
,
Lukashev
A
,
Iggo
RD
. 
RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer
.
Cancer Res
2005
;
65
:
6882
90
.
32
Mabuchi
S
,
Altomare
DA
,
Cheung
M
, et al
. 
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
.
Clin Cancer Res
2007
;
13
:
4261
70
.
33
Papewalis
C
,
Wuttke
M
,
Schinner
S
, et al
. 
Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer
.
Horm Metab Res
2009
;
41
:
752
6
.
34
Konings
IR
,
Verweij
J
,
Wiemer
EA
,
Sleijfer
S
. 
The applicability of mTOR inhibition in solid tumors
.
Curr Cancer Drug Targets
2009
;
9
:
439
50
.
35
Mabuchi
S
,
Altomare
DA
,
Connolly
DC
, et al
. 
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
.
Cancer Res
2007
;
67
:
2408
13
.
36
Tam
KH
,
Yang
ZF
,
Lau
CK
,
Lam
CT
,
Pang
RW
,
Poon
RT
. 
Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma
.
Cancer Lett
2009
;
273
:
201
9
.
37
Wolpin
BM
,
Hezel
AF
,
Abrams
T
, et al
. 
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
.
J Clin Oncol
2009
;
27
:
193
8
.
38
Milano
V
,
Piao
Y
,
LaFortune
T
,
de Groot
J
. 
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
.
Mol Cancer Ther
2009
;
8
:
394
406
.
39
Mazzanti
R
,
Platini
F
,
Bottini
C
,
Fantappie
O
,
Solazzo
M
,
Tessitore
L
. 
Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line
.
Biochem Pharmacol
2009
;
78
:
21
32
.
40
Ito
H
,
Daido
S
,
Kanzawa
T
,
Kondo
S
,
Kondo
Y
. 
Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells
.
Int J Oncol
2005
;
26
:
1401
10
.
41
Kim
KW
,
Mutter
RW
,
Cao
C
, et al
. 
Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling
.
J Biol Chem
2006
;
281
:
36883
90
.
42
Kim
KW
,
Hwang
M
,
Moretti
L
,
Jaboin
JJ
,
Cha
YI
,
Lu
B
. 
Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer
.
Autophagy
2008
;
4
:
659
68
.
43
Yao
KC
,
Komata
T
,
Kondo
Y
,
Kanzawa
T
,
Kondo
S
,
Germano
IM
. 
Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy
.
J Neurosurg
2003
;
98
:
378
84
.
44
Cao
C
,
Subhawong
T
,
Albert
JM
, et al
. 
Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells
.
Cancer Res
2006
;
66
:
10040
7
.
45
Shimizu
S
,
Kanaseki
T
,
Mizushima
N
, et al
. 
Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes
.
Nat Cell Biol
2004
;
6
:
1221
8
.
46
Levine
B
,
Yuan
J
. 
Autophagy in cell death: an innocent convict?
J Clin Invest
2005
;
115
:
2679
88
.
47
Rubio-Viqueira
B
,
Hidalgo
M
. 
Targeting mTOR for cancer treatment
.
Curr Opin Investig Drugs
2006
;
7
:
501
12
.